ストックスクリーナーアプリを入手
13.40
0.00%
0.00
前日終値:
$13.40
開ける：
$13.39
24時間の取引高:
310.53K
Relative Volume:
0.66
時価総額：
$729.17M
収益：
-
当期純損益:
-
株価収益率:
-
EPS:
-
ネットキャッシュフロー:
-
1週間 パフォーマンス:
+1.21%
1か月 パフォーマンス:
+8.41%
6か月 パフォーマンス:
-47.33%
1年 パフォーマンス:
+0.00%
1日の値動き範囲:
$13.03
$14.39
1週間の範囲:
$12.56
$14.39
52週間の値動き範囲:
$11.10
$28.09
Bicara Therapeutics Inc Stock (BCAX) Company Profile
BCAX を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
BCAX
Bicara Therapeutics Inc
|
13.40 | 729.17M | 0 | 0 | 0 | 0.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
492.69 | 131.41B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
637.36 | 72.26B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
589.15 | 35.93B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
268.46 | 34.75B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
267.39 | 28.24B | 3.81B | -644.79M | -669.77M | -6.24 |
Bicara Therapeutics Inc Stock (BCAX) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-02-06 | 開始されました | Wedbush | Outperform |
| 2024-12-06 | 開始されました | H.C. Wainwright | Buy |
| 2024-11-05 | 開始されました | Rodman & Renshaw | Buy |
| 2024-10-08 | 開始されました | Cantor Fitzgerald | Overweight |
| 2024-10-08 | 開始されました | Morgan Stanley | Overweight |
| 2024-10-08 | 開始されました | Stifel | Buy |
| 2024-10-08 | 開始されました | TD Cowen | Buy |
すべてを表示
Bicara Therapeutics Inc (BCAX) 最新ニュース
Bicara Therapeutics (NASDAQ:BCAX) Earns Outperform Rating from Wedbush - Defense World
Charles Schwab Investment Management Inc. Takes Position in Bicara Therapeutics Inc. (NASDAQ:BCAX) - Defense World
Stifel raises Bicara stock price target to $48, maintains Buy By Investing.com - Investing.com Canada
Bicara Therapeutics Reports Strong Financial Position and Clinical Progress - TipRanks
Analysts Adjust Price Targets For Nkarta And Bicara - Evrim Ağacı
Stifel raises Bicara stock price target to $48, maintains Buy - Investing.com India
Bank of New York Mellon Corp Makes New Investment in Bicara Therapeutics Inc. (NASDAQ:BCAX) - Defense World
Bicara Therapeutics Inc QTRLY Loss Per Share $0.39 - Marketscreener.com
Bicara Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update - GlobeNewswire
Bicara Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides ... - Enid News & Eagle
Bicara Therapeutics Announces Upcoming Presentations at AACR Annual Meeting 2025 - GlobeNewswire
Skandinaviska Enskilda Banken AB publ Purchases Shares of 38,035 Bicara Therapeutics Inc. (NASDAQ:BCAX) - MarketBeat
Bicara Therapeutics Inc (BCAX): A New Perspective - Stocks Register
Cantor Fitzgerald Reiterates “Overweight” Rating for Bicara Therapeutics (NASDAQ:BCAX) - Defense World
Bicara Therapeutics Inc. (NASDAQ:BCAX) Receives $41.20 Consensus Price Target from Analysts - Defense World
Cantor Fitzgerald maintains Overweight on Bicara Therapeutics By Investing.com - Investing.com Canada
Cantor Fitzgerald maintains Overweight on Bicara Therapeutics - Investing.com India
Companies Like Bicara Therapeutics (NASDAQ:BCAX) Are In A Position To Invest In Growth - Yahoo Finance
19,008 Shares in Bicara Therapeutics Inc. (NASDAQ:BCAX) Purchased by Rhumbline Advisers - Defense World
Bicara Therapeutics Inc.’s (NASDAQ:BCAX) Lock-Up Period Set To Expire on March 12th - Defense World
Bicara Therapeutics to Present at the TD Cowen 45th Annual Health Care Conference - The Manila Times
Bicara Therapeutics (BCAX) Expected to Announce Quarterly Earnings on Tuesday - Defense World
Bicara Therapeutics Inc. (NASDAQ:BCAX) Receives Consensus Rating of "Buy" from Analysts - MarketBeat
Bicara Therapeutics Inc. (NASDAQ:BCAX) Receives $41.20 Consensus PT from Analysts - Defense World
Bicara Therapeutic, Inc. announced that it has received $108.234983 million in funding from a group of investors - Marketscreener.com
Bicara Therapeutics (NASDAQ:BCAX) Receives Outperform Rating from Wedbush - MarketBeat
Bicara Therapeutics (NASDAQ:BCAX) Stock Price Down 8.6%Here's Why - MarketBeat
Bicara Therapeutics (NASDAQ:BCAX) Shares Up 7.3%Should You Buy? - MarketBeat
Wedbush Reiterates Outperform Rating for Bicara Therapeutics (NASDAQ:BCAX) - Defense World
Bicara Therapeutics Announces First Patients Enrolled in - GlobeNewswire
Major Cancer Treatment Breakthrough? Phase 2/3 Trial Launches for Advanced Head & Neck Cancer - StockTitan
Bicara Therapeutics Announces First Patients Enrolled in FORTIFI-HN01, a Pivotal Phase 2/3 Clinical Trial of Ficerafusp Alfa in 1L Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma - Investing.com UK
Bicara Therapeutics (NASDAQ:BCAX) Upgraded to Strong-Buy at Wedbush - MarketBeat
Bicara Therapeutics (BCAX) Projected to Post Quarterly Earnings on Tuesday - Defense World
Bicara Therapeutics (NASDAQ:BCAX) Coverage Initiated at Wedbush - MarketBeat
Wedbush Begins Coverage on Bicara Therapeutics (NASDAQ:BCAX) - Defense World
Wedbush Upgrades Bicara Therapeutics (NASDAQ:BCAX) to “Strong-Buy” - Armenian Reporter
Bicara Therapeutics (BCAX) to Release Earnings on Tuesday - MarketBeat
Wedbush Initiates Coverage of Bicara Therapeutics (BCAX) with Outperform Recommendation - Nasdaq
Wedbush Initiates Coverage on Bicara Therapeutics With Outperform, $31 Price Target - Marketscreener.com
Bicara Therapeutics (NASDAQ:BCAX) Stock Price Up 9.7%Should You Buy? - MarketBeat
Bicara reports positive Phase 1/1b trial results for cancer therapy - MSN
Bicara Therapeutics: A Decline Off The IPO Spells 'Wait' For Me (NASDAQ:BCAX) - Seeking Alpha
H.C. Wainwright lifts Bicara stock target to $45, maintains buy - MSN
Bicara Therapeutics (NASDAQ:BCAX) Hits New 52-Week LowTime to Sell? - MarketBeat
Bicara Therapeutics price target raised to $45 from $42 at H.C. Wainwright - MSN
Bicara Therapeutics Presents Phase 1/1B Dose Expansion Results with Ficerafusp Alfa in Advanced Squamous Cancer of the Anal Canal At the 2025 Asco Gastrointestinal Cancers Symposium - Marketscreener.com
Bicara Therapeutics Inc (BCAX) 財務データ
Bicara Therapeutics Inc (BCAX) の財務データはありません。詳細については、他の銘柄を確認してください。
収益
当期純利益
現金流量
EPS
Bicara Therapeutics Inc (BCAX) インサイダートレーディング
| インサイダートレーディング | 関係 | 日付 | 取引 | コスト | #株式 | 値 ($) | #株式総数 |
|---|---|---|---|---|---|---|---|
| Meisner Lara | Chief Legal Officer |
Mar 14 '25 |
Sale |
12.90 |
79,146 |
1,021,211 |
0 |
0.39%
0.34%
大文字化:
|
ボリューム (24 時間):